Πέμπτη 26 Μαρτίου 2020

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia: The β-thalassemias are a group of inherited hemoglobin disorders that represent a substantial global health burden. Defective production of β-globin chains of adult hemoglobin causes an imbalanced ratio of α-globin to β-globin. Genetic mutations and secondary modifiers that affect this imbalance…


Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου